

- 2) Patients who had diagnosed malignant tumours before COVID-19 infection,
- 3) Patients who had history of using immunosuppressive agents.

The conventional treatment:

- 1 Antivirals (Favipiravir, 2x1600 mg loading dose, and 2x600 mg maintenance 5 days)
- 2 Dexamethasone (1X6mg IV 5-10days per needed)
- 3 Enoxaparine (1X0.6 ml)
- 4 Antibiotics were given according to the results of the antibiogram if there was a secondary infection.

Stem cell processing, quality control and preparation

isolated, expanded, analysed, and prepared in the cGMP-FHUWLHG IDFLWLW\DW /LY RVSLWDO &HQVHU IRU 5HHGUDWLYH Medicine and Stem Cell Manufacturing (LivMedCell) as described previously (9,10). The MSCs were slowly drawn into the syringe without pressure having 40 ml volume and VXVSHQHGLPQRIID&O

Outcome Measures

- a) Any allergic reaction, adverse events related to MSCs transplant
- b) Any allergic reaction, adverse events related to MSCs transplant
- d) Length of stay in hospital
- e) Mortality rates and reasons

Biochemical parameters

Hemogram, alanine transaminase (ALT), aspartate transaminase (AST), total protein, albumin, total bilirubin, direct bilirubin, ferritin, Triglycerides, D Dimer, troponin, myoglobin, procalcitonin (PCT), ammonia, C reactive protein (CRP), creatin kinaz (CK), alkaline phosphatase (ALP) levels were determined using Beckman Coulter AU5800 clinical chemistry analyzer (Beckman Coulter, Brea, CA, USA). A complete blood count (CBC) was analysed with ADVIA 2120i hematology autoanalyzer (Siemens Healthcare Diagnostics, Erlangen, Germany).

Statistical analysis

(Kaysville, Utah, USA) program was used for statistical analysis. Descriptive statistical methods (mean, standard deviation, median, frequency, percentage, minimum, maximum) were used while evaluating the study data. The conformity of the quantitative data to the normal distribution

was tested with the Shapiro-Wilk test and graphical examinations. One-way Anova was used for the comparison of normally distributed variables between three groups. The Kruskal Wallis test was used for the comparison of the non-normally distributed variables between three groups. Pearson chi-square test and Fisher-Freeman-Halton Exact test were accepted as p<0,05.

Results

Patients characteristics

A total of 104 patients were enrolled in this study, 26 of 104 patients were female (25%) and 78 were male (75%), with a mean age of 54 years. When the groups were compared

Laboratory Assessments

COVID-19 infection markers: Serum levels of troponin, procalcitonin (PCT), CRP (C-Reaktif Protein), D-dimer, in all patients with COVID-19 infection. When compared between the groups, the CRP level of group-1 was found to be lower than the other groups (p<0.05) at the last dose of MSCs were compared between groups, there was no statistically VLDQW GLuHUHQH S!7DEOH 'GLPHU OHYHOV were compared between groups, the group-1 values were found to be statistically lower (p<0.05) than group 2 and group 3. According to the groups, the 1st, 2nd and 3rd time lymphocyte and white basal cells count measurements of WKHSDWLHQV VGLGRVWVKRZDVWDWLWVLFDOOVLDFDQG GXULQKLVSHULRGS).

Patients situation and mortality

We used the Apache-2 score to determine patients' current physiological status and disease severity related to COVID-19. In addition, the lung functions of the patients were evaluated with the Horowitz index. When the Apache-2 and Horowitz Index of the patients followed in the intensive care unit were compared at the beginning of the study, there ZDV QVVDWLWVLFDOO\LDQW GLuHUHQH S, QXU study, 54 (52%) of 104 patients died and 50 patients (48%) were discharged with clinical and laboratory (PCR-) recovery. When we evaluated the mortality rates between the groups, 10 patients (31%) in group-1, 20 patients (56%) in group-2 and 24 patients (67%) in group-3 died, respectively (Table-3, Figure-2). When groups were compared, the mortality rate in group-1 was found to be statistically lower (p<0.05) than the other groups (Table-3). When the causes of death of the patients are evaluated, secondary infections due to bacteria, DQ UHODWHG VHSVLV FRPH UVW IROORZHG E\PRFDUGI infarction, thromboembolism, and multi-organ failure.

Table 1: Distribution of Demographic Characteristics and length of hospital stay by groups. NS: non-significant.

		Groups			P
		Group-1	Group-2	Group-3	
		n=32	n=36	N=36	
Age (years)	Mean±Sd	50,8±13,5	54,3±11,4	56,1±10,9	^a NS
	(Median) Min-Max	52(23-77)	53,5 (24-76)	57 (25-84)	
Gender n (%)	Male	23 (72)	28 (78)	27 (75)	^b NS
	Female	9 (28)	8 (22)	9 (25)	
Length of Hospital Stay	Mean±Sd	27±12,5	28±13,4	26±11,6	^c NS
	(Median)	26 (9-58)	24 (9-70)	21 (12-55)	
	Min-Max				

^aOneway Anova, ^bPearson Chi-Square Test, ^cKruskal Wallis Test.

Table 2: Level of inflammation markers in venous blood samples, p values following comparison between groups. All values are given as minimum, maximum, median and mean, NS: not significant.

		Group 1	Group 2	Group 3	^a P
CRP (mg/L)					
Day 1		122±115,2	129±80,3	146±85,4	NS
		82 (6,2-390)	110 (3-358)	138 (6-327)	
Day 4	Mean±Sd	78±89,2	86±99,7	87±84,6	NS
	(Median) Min-Max	59 (1-223)	68 (1,5-324,9)	73 (1,4-275)	
Day 7		58±85,7	94±113,5	70±72,3	^a <0,05
		35 (1,6-172,5)	39 (2-352)	51 (2-221)	
PCT (ng/mL)					
Day 1		0,6±1,2	2,4±7,9	0,5±0,5	NS
		0,2 (0,04-4,4)	0,3 (0,04-4,7)	0,2 (0,06-2,4)	
Day 4	Mean±Sd	4,5±18,1	4,9±22,2	3,3±13,7	NS
	(Median) Min-Max	0,16 (0,02-100)	0,2 (0,04-124)	0,2 (0,03-59)	
Day 7		3,8±13,4	3,2±7,22	3,7±10,7	NS
		0,3 (0,02-60)	0,2 (0,02-32)	0,4 (0,01-41)	
D-Dimer (µg/ml)					
Day 1		1,9±2,8	2,1±1,7	2,5±2,6	^a <0,05
		0,7 (0,1-10,4)	1,4 (0,1-7,2)	1,5 (0,3-13,3)	
Day 4	Mean±Sd	1,7±1,6	2,6±2	2,1±1,2	^a <0,05
	(Median) Min-Max	0,9 (0,4-6)	2 (0,2-9)	1,6 (0,1-6)	
Day 7		1,7±1,71	2,2±1,96	2±1,13	^a <0,05
		1,4 (0,4-5,3)	1,5 (0,4-7,9)	1,7 (0,2-3,9)	
Fibrinojen (mg/dL)					
Day 1		575±224	596±159	613±193	NS
		517 (128-1198)	572 (181-968)	635 (247-1113)	
Day 4	Mean±Sd	504±203	479±246	502±171	NS
	(Median) Min-Max	475 (217-969)	416 (158-1200)	497 (72-797)	
Day 7		507±244	488±212	538±116	NS
		490 (209-1140)	421 (239-1040)	505 (401-745)	
Ferritin (µg/L)					
Day 1		824±783	1813±1838	1170±895	^a <0,05
		627 (71-3761)	1654 (188-9515)	724 (209-3237)	
Day 4	Mean±Sd	1096±2635	999±1044	1019±1008	NS
	(Median) Min-Max	509 (133-14665)	780(53-5341)	548 (67-3851)	
Day 7		1355±2236	1315±2985	2037±4331	NS
		534 (205-15316)	620(112-14431)	514 (63-16188)	

^aKruskal Wallis Test.

Table 3: The number of mortality according to the initial day of MSCs administration, while no death was observed in patients who received MSCs transplant on day-1, the highest mortality rate was observed in patients who were given on the last day [12].

Group-1 (n:32)						p
Initial day of MSCs transplantation	1 st day	2 nd day	3 rd day	4 th day	Total Death Number (%)	
Mortality number	0	2	4	4	10 (%31)	
Group-2 (n:36)						
Initial day of MSCs transplantation	5 th day	6 th day	7 th day	8 th day	Total Death Number (%)	
Mortality number	4	5	6	5	20 (%56)	
Group-3 (n:36)						
Initial day of MSCs transplantation	9 th day	10 th day	11 th day	12 th day	Total Death Number (%)	
Mortality number	6	5	5	8	24 (%67)	
Total death number					54 (%52)	P<0.05




Figure 2: The number of deaths according to the first day of MSCs administration among the groups, the lowest mortality was found in group-1, while the highest mortality was in group-3 (p<0.05).

When the average hospital stay of the patients was compared, they were 27 days in group-1, 28 days in group 2, and 26 days in group-3, respectively, and no statistical difference was found (p>0,05) (Table 1).

Discussion

Mesenchymal stem cells could play a pivotal role in combating COVID-19 because of its immunomodulation and regenerative potential as depicted. The immunomodulatory

characteristic of MSCs indicate that MSCs can be used as a supportive treatment option for better recovery of critically ill COVID-19 patients (11,12). As of today, there are no detailed and precise data regarding the dose of MSCs and the route of administration in critically ill patients with COVID-19 infection. Furthermore, there is no consensus on which time is the optimal time to begin MSC administration in critically ill patients with COVID-19 infection. The aim of this study was to find the answer to when MSCs should be given to

critically ill patients with COVID-19 infection. For this purpose, MSCs were applied to critically ill patients with COVID-19 infection in 3 different time periods, and it was investigated which of these time periods had a more positive effect on recovery. We used the Apache-2 score to determine the patients current physiological state and overall disease severity. In addition, the lung function of the patients in the groups was evaluated with the Horowitz index. This index is useful for assessing the extent of damage to the lungs. The Horowitz index plays a major role in the diagnosis of acute respiratory distress syndrome (ARDS) (8). When the Apache-2 and Horowitz Index of the patients followed in the ICU were compared at the beginning of the MSCs treatment, it was found that there was no statistically significant difference. This result shows that the distribution of patients between the groups is homogeneous. The dose of injected cells ranges generally from 0,5 to 2x10⁶ cells/kg. Apart from these studies, there have been publications using higher MSCs. The number of injections varies between a single dose and up to 4 doses. In general, the interval between repeat injections ranges from 24h to 96 h, which is common [13,14]. In our study, 3x10⁶/kg MSCs were administered as 3 same doses with 3 day intervals [15]. Our clinical practice for the treatment of MSCs is to give to critically ill COVID-19 patients admitted to the ICU. Although it has been given in some centers in the literature, especially in comorbid patients, we do not apply MSCs treatment to mild or moderate patients with good general condition. In general, we prefer to start MSCs treatment within the first 48 hours in intubated patients with COVID-19 infection [15]. One of the hallmarks of COVID-19 is high serum concentrations of CRP (16). In our study, when all groups were evaluated as COVID-19 infection markers, the CRP level of group-1 was found to be lower than the other groups. This level of decrease was statistically significant in favor of group-1 in the last MSCs (3rd dose) administration ($p<0.05$) (Table-2). An elevated D-dimer, the most common coagulation abnormality in COVID-19 is an independent risk factor for death [17]. When D-dimer levels were compared between the groups, group-1 values were found to be statistically lower than the other groups ($p<0.05$) (Table-2). These results show the positive effect of MSCs applied in the early period on both COVID-19 infection markers. MSCs are now being used as a potential therapy for treating COVID-19 patients in order to reduce mortality. Generally critically ill patients, and those patients who are at high risk of infection due to other comorbidities, are potential candidates for stem cell-based therapies [18,19]. However, no data is currently available regarding the time of the start of MSC therapy for maximum benefits [19]. In our study, considering the mortality numbers and rates, the highest mortality rate was 24 patients (%67) in group-3. The lowest mortality rate was in group-1 with 10 patients (%31). When the groups were compared statistically, the mortality rate in group-1 was found to be statistically ($p<0,05$) low. This result

shows that MSCs transplantation at an earlier time period reduces mortality in patients with critical COVID-19 infection. In the late period, especially after the first week, the positive effect of MSC transplantation on mortality decreases considerably. This can be explained by the fact that the effect of MSCs on organ regeneration has decreased considerably. These patients especially had multiple organ failure. When the MSCs application initial time is determined, it is seen that MSCs treatment was given to the patients on 12 separate days. When this situation was evaluated, it was observed that the number of mortality increased especially in the late period in group-3. While there was no mortality in the patients who started MSCs on the 1st day of administration, 8 deaths occurred in the patients who were administered on the 12th day (Table-3, Figure-1). This result is that the application of MSCs has no positive effect on improvement in patients with COVID-19 in the late period. The lowest mortality rate (31%) in group-1 is close to the result (%30) of our previously published prospective double control study on this subject [15]. Both results support early initiation of MSCs therapy in critically ill patients with COVID-19 infection. Leng et al. investigated the use of MSCs in hospitalized patients with COVID 19 who were not improving despite standard therapy. Intravenous MSC at a dose of 1x10⁶ cells per kg was administered to seven patients in the early period. MSC infusion was well tolerated all the patients [20]. Sanchez-Guijo et al administered MSCs to thirteen adult Covid-19 patients undergoing invasive mechanical ventilation. Ten of the thirteen patients received two doses (3 days after the first dose). The remaining two patients received a single dose, while the third patient received 3 doses of MSC. While 70% of the patients recovered clinically and were discharged from the intensive care unit, four patients remained intubated and two patients died [21]. As a matter of discussion in this study, it may be asked why treatment for MSCs is not started early and in the same time period to all patients. Our hospital is accepted as a reference center since it is a hospital that provides cellular treatments in Istanbul. For this reason, critical patients with COVID-19 infections are transferred from surrounding hospitals and nearby provinces. In this study, our main goal is to reduce the mortality rate with treatment of MSCs in critically ill COVID-19 patients. These patients were treated with cellular based therapy as one of the last options, since conventional treatments related to COVID-19 had been performed before. Therefore, MSCs treatment initiation time differs in patients. This is one of the limitations of our study. When the average hospital stay of the patients was compared, they were 27 days in group-1, 28 days in group 2, and 26 days in group-3, respectively, and no statistical difference was found ($p>0,05$). It is seen that the shortest mean duration of stay was in group-3 with 26 days. The reason for this is that the highest death rate is in group-3, which decreases on average. As it is known, the most frequently affected main organ in COVID 19 infection is the

lungs. Our opinion is that this is an advantage in favor of systemic MSCs transplantation. Because the vast majority of systemically administered cells are trapped inside the lungs [22,23]. Exogenously given MSCs trapped in the lungs allow stem cell based therapy to be faster and more efficient on COVID-19 infection. This makes it advantageous to apply stem cell-based therapy in COVID-19. The main limitation of our study is that it is a retrospective study. In addition, the transfer of our patients from many different centers to our hospital negatively affects the homogeneity of the study in terms of the start time of the MSC application. The patients transferred to our hospital were generally in poor general condition and were treated with classical treatments for COVID-19 infection. For this reason, our thought in administering MSCs to patients, even in the late period, is to benefit from the regeneration effect of these cells. We also predicted that the positive effect of MSC on regeneration would reduce mortality. MSCs can secrete a variety of growth factors have significant ability to play essential roles in tissue regeneration in lung injuries via diminishing collagen accumulation and fibrosis [24]. Systemic administration of MSCs results in homing to the pulmonary vascular bed where they release soluble factors such as antiinflammatory cytokines, antimicrobial peptides, angiogenic growth factors, and extracellular vesicles and thus could improve the pulmonary microenvironment, protect alveolar epithelial cells, prevent pulmonary fibrosis and improve overall lung function [19,25]. One of our reason for applying MSCs in the late period was to use the reducing effect of these cells on lung fibrosis. However, in our study, we did not find a reducing effect of MSC treatment on mortality, especially in the last time period. As we mentioned in our previously published study, the first 48 hours of MSCs treatment is to start in critically ill patients with COVID-19 who are taken to intensive care and intubated. The results of both studies show that the optimal time to administer MSCs in critically ill patients with COVID-19 is the first 48 hours. Apart from this, we predict the initiation of MSCs treatment in patients who are considered to be transferred to the intensive care unit, where the respiratory parameters and vital functions of the patient begin to deteriorate and the cytokine storm continues.

Conclusion

In conclusion, early initiation of MSC treatment reduces mortality in critically ill patients with COVID-19 who have impaired vital signs and are admitted to the intensive care unit. As treatment initiation time increases, the efficacy of MSCs may decrease or become ineffective.

Abbreviations

MSC: mesenchymal stem cells

ARDS: Acute respiratory distress syndrome

e-CDSS: electronic clinical decision support system

PBW: predicted body weight

PEEP: Positive End Expiratory Pressure

Apache-2 score: Acute Physiology and Chronic Health Evaluation Score

Horowitz Index: $\text{PaO}_2/\text{FiO}_2$

CRP: C-Reaktif Protein

PCT: Procalcitonin

Compliance with ethical standards

Funding

No funding was received for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

1. Kumar A, Ghosh B S. Emerging Treatment Options of Regenerative Medicine in Severe Corona Virus/COVID 19 Infections. *International Journal of Stem Cells* 31 (2020): 12-23
2. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol* 12 (2017): 67-81.
3. Irmak KD, Darici H, Karaoz E. Stem cell based therapy option in COVID-19: Is it really promising? *Aging and Disease* 4 (2020): 1-17.
4. Laroye C, Gibot S, Huselstein C, et al. Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19. *Stem Cells Transl Med* 9 (2020): 1488-1494.
5. Xia S, Zhou C, Kalionis B, et al. Combined antioxidant, anti-inflammaging and mesenchymal stem cell treatment: A possible therapeutic direction in elderly patients with chronic obstructive pulmonary disease. *Aging and Disease* 11 (2020): 129-140.
6. Ahmed MS, Morsi M, Ghoneim IN, et al. Mesenchymal stromal cell therapy for pancreatitis: A systemic review.

- Oxidative Medicine and Cellular Longevity 13 (2018): 1-14.
7. Behnke J, Kremer S, Shahzad T, et al. MSC based therapies-new perspectives for the injured lung. *J of Clin Med* 13 (2020): 32-45.
 8. Ranieri VM, Rubenfeld GD, et al. ARDS definition Task Force, Acute respiratory distress syndrome: Berlin Definition. *JAMA* 307 (2012): 2526-2533.
 9. Dai A, Baspınar O, Yeşilyurt A, et al. Efficacy of stem cell therapy in ambulatory and nonambulatory children with Duchenne muscular dystrophy—Phase I–II. *Degenerative Neurological and Neuromuscular Disease* 8 (2018): 63-77.
 10. Kabatas S, Civelek E, İnci Ç, et al. Wharton's Jelly-Derived Mesenchymal Stem Cell Transplantation in a Patient with Hypoxic-Ischemic Encephalopathy: A Pilot Study. *Cell Transplantation* 27 (2018): 1425-1433.
 11. Pooja Y, Ravina V, Afsareen B, et al. Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. *Life Sci* 263 (2020): 118588.
 12. Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. *Medicine* 99 (2020): e21429
 13. Khoury M, Ikononou L, Dominici M, et al. The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products? *Stem Cells and Development* 30 (2019): 887-899
 14. Shahani P, Datta I. Mesenchymal stromal cell therapy for coronavirus disease 2019: which? when? and how much? *Cytotherapy* 23 (2021): 861-873.
 15. Adas G, Z Cukurova, K Kart et al. The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial *Cell Transplant* 30 (2021): 456-469.
 16. Zhand S, Jazi MS, Mohammadi S, et al. COVID-19: The immune responses and Clinical Therapy Candidates. *Int J Mol Sci* 34 (2020): 21-15.
 17. Meaghan EC, Yogendra K. COVID-19 associated coagulopathy: An exploration of mechanisms *Vascular Medicine* 25 (2020): 471-478.
 18. Zumla A, Wang SF, Ippolito G, et al. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies *Int J Infect Dis.* 96 (2020): 431-439.
 19. Choudhery SM, Harris TD. Stem cell therapy for COVID-19: possibilities and challenges. *Cell Biol Int* 44 (2020): 2182-2191.
 20. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. *Aging and Disease* 11 (2020): 216.
 21. Mallis P, Michalopoulos E, Chatzistamatiou T, et al. Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection. *World J Stem Cells* 12 (2020): 731-751.
 22. Schrepfer S, Deuse T, Reichenspurner H, et al. Pelletier Stem Cell Transplantation: The Lung Barrier. *Transplantation Proceedings* 39 (2007): 573-576.
 23. Fischer MU, Harting TM, Jimenez F, et al. Pulmonary Passage is a Major Obstacle for Intravenous Stem Cell Delivery: The Pulmonary First-Pass Effect. *Stem Cells and Development* 18 (2009): 681-693.
 24. Susan M, Atieh P, Parisa Z, et al. Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities *International Immunopharmacology* 97 (2021): 107694
 25. Lanzoni G, Linetsky E, Correa D, et al. Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS). *CellR4 Repair Replace Regen Reprogram.* 8 (2020): 459-471.